10 Conclusions and clinical take-home messages 10.1 Main findings: certainties amidst uncertainties Synthesizing the current evidence, the information architecture regarding GLP-1RAs in PCOS fertility management exhibits a characteristic gradient: robust metabolic evidence, hypothesis-generating reproductive findings, and a gray zone of safety. Robust metabolic benefit: in overweight or obese PCOS phenotypes, evidence for the improvement of metabolic endpointsincluding body weight, central adiposity, and IRis consistently positive, facilitating the establishment of actionable therapeutic goals (e.g., reaching clinically significant weight-loss thresholds and optimizing IR markers)
& Yada, T
BPC-157 Regulatory Status BPC-157 has never received an Investigational New Drug (IND) application approval from the FDA for human use
The incidence of these side effects increased with higher doses
Your weight should be stable
J., Bergenstal, R., Bode, B